Navigation Links
Peramivir in Medical News

BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza

A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) pe...

BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update

... and potential emergency use of intravenous (i.v.) peramivir in the U.S. "Our efforts at BioCryst remain focused on moving our leading peramivir and forodesine clinical development programs forwa...iligently with government agencies to provide i.v. peramivir as a potential treatment option for an influenza e...

BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008

...ear contract to BioCryst to advance development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that the...

BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...

BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

...n have a new form of anti-viral therapy to effectively manage the bird flu threat. "The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza...
Peramivir in Medical Technology

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009

BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza...

BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza

BIRMINGHAM, Ala., July 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II tria...

BioCryst Updates Peramivir Clinical Development Plan

BIRMINGHAM, Ala., Jan. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today provided an update on activities conducted following release of the preliminary Phase II data and outlined the resulting clinical development plan for intramuscular (i.m.) peramivir. (Lo...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramusc...

Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma

...r contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. ...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection ...be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary res...
Peramivir in Biological News

Peramivir protects mice from lethal H5N1 infection

... The antiviral drug peramivir might offer humans significant protection during a...day versus eight days); route of administration of peramivir (intramuscular injections alone versus intramuscul...ice). In all cases, the investigators administered peramivir to mice one hour after nasally administering a let...
Peramivir in Biological Technology

BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza

BIRMINGHAM, Ala., Sept. 19 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced preliminary findings from a Phase II study with intramuscular (i.m.) injection of peramivir, the Company's product candidate for the treatment of seasonal and life-threatening i...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs and a reduction in cos...red in the Phase 3 program of intramuscular (i.m.) peramivir for outpatient influenza. The Company initiated t...

BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

...at many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

...0, 2007. This decrease is driven by a reduction in peramivir clinical development costs and associated revenue ... in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in cost...

BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza

...ty of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in ...ficacy endpoints between the three treatment arms. peramivir was generally safe and well-tolerated at these dos...

BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

...ble-Blind, Placebo-Controlled Study of Intravenous peramivir in Acute Influenza Patients" (Poster Session # 302...y and Pharmaceutical Sciences. About Peramivir peramivir is an antiviral agent that inhibits the interactio...d of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are ...

BioCryst to Present at the JMP Healthcare Focus Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...

BioCryst to Present at UBS 2008 Global Life Sciences Conference

...t many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular i...ndition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the pe...
Other Tags
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... 30, 2014 Good Neighbor Community ... an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , In this ... Community Services’ vision to redefine the traditional approach ... dynamic services. Through passion, innovation, determination, excellence, and ...
(Date:7/30/2014)... It can happen in an instant: A small child pulls ... gets critically injured when the furniture tips over. "Every ... their homes and imagine what could tip over, fall off ... it becoming a reality," Dr. Alex Rosenau, president of the ... release. Between 2009 and 2011, roughly 43,000 people ended ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
Other Contents